Rubina Aqeel, MD
Endocrinology, Diabetes & Metabolism · Upland, CANPI 1407972490
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $16,669 of the $23,139 with a category attached, or 72.0%. Ascendis Pharma Endocrinology Inc accounts for 74.1% of it on its own, with 37 other manufacturers making up the rest. 2025 is the largest year on record at $17,754, more than ten times the $558 reported in 2019.
Across 331 payments — averaging $69.90 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ascendis Pharma Endocrinology Inc$17K
- Novo Nordisk$1K
- Sanofi-aventis U.S. LLC$572
- Antares Pharma, Inc.$529
- Corcept Therapeutics$377
- Amgen$287
- plus $3K from 32 others
What the payments were for
- Speaking & faculty fees$16,66972%
- Food & beverage$6,37228%
- Education$380%
- Gifts$590%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ascendis Pharma Endocrinology Inc | 24 | $17,150 |
| Novo Nordisk | 64 | $1,101 |
| Sanofi-aventis U.S. LLC | 42 | $572 |
| Antares Pharma, Inc. | 14 | $529 |
| Corcept Therapeutics | 17 | $377 |
| Amgen(2 entities) | 14 | $287 |
| Abbott | 19 | $245 |
| Recordati_rare_diseases_inc. | 12 | $235 |
| Lilly USA, LLC | 10 | $222 |
| Merck | 10 | $200 |
| Mannkind Corporation | 8 | $187 |
| Boehringer Ingelheim | 9 | $183 |
| Kyowa Kirin, Inc. | 5 | $169 |
| Bayer | 8 | $162 |
| AstraZeneca(2 entities) | 8 | $148 |
| Dexcom, Inc. | 8 | $145 |
| Radius Health, Inc. | 5 | $134 |
| AbbVie | 6 | $119 |
| Xeris Pharmaceuticals, Inc. | 6 | $111 |
| Insulet Corporation | 5 | $96 |
| Pfizer | 4 | $92 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $85 |
| Alvogen Inc | 4 | $77 |
| Medtronic | 3 | $68 |
| Ipsen Biopharmaceuticals, Inc | 3 | $60 |
| Amryt Pharma Holdings Ltd | 3 | $60 |
| Neurocrine Biosciences, Inc. | 2 | $56 |
| Acerus Pharmaceuticals Corporation | 2 | $43 |
| Johnson & Johnson | 2 | $39 |
| Cequr Corporation | 2 | $33 |
| Tolmar, Inc. | 2 | $29 |
| Sequel Med Tech, LLC | 1 | $22 |
| Clarus Therapeutics Inc. | 1 | $21 |
| GSK | 1 | $21 |
| Acella Pharmaceuticals, LLC | 1 | $19 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Sun Pharmaceutical Industries Inc. | 1 | $15 |
| GRT US Holding, Inc. | 1 | $8 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$23,139 in reported general payments places this provider in the 85th percentile of 952 endocrinology, diabetes & metabolism providers in California.
See all endocrinology, diabetes & metabolism providers in California →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 245 | $304,127 |
| JardianceEmpagliflozin | 82 | $101,281 |
| Somatuline DepotLanreotide Acetate | 12 | $90,962 |
| FarxigaDapagliflozin Propanediol | 80 | $84,706 |
| MounjaroTirzepatide | 61 | $70,846 |
| ProliaDenosumab | 26 | $43,643 |
| Teriparatide | 20 | $39,963 |
| RybelsusSemaglutide | 21 | $33,711 |
| TrulicityDulaglutide | 32 | $33,391 |
| JanuviaSitagliptin Phosphate | 29 | $30,805 |
| TradjentaLinagliptin | 32 | $30,386 |
| Tresiba Flextouch U-100Insulin Degludec | 32 | $26,842 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 27 | $25,131 |
| Tresiba Flextouch U-200Insulin Degludec | 11 | $21,090 |
| Cinacalcet Hcl | 43 | $16,314 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,101 | $337,838266 claims |
| Boehringer IngelheimJardiance, Tradjenta | $183 | $131,667114 claims |
| Lilly USA, LLCMounjaro, Trulicity | $222 | $104,23793 claims |
| Ipsen Biopharmaceuticals, IncSomatuline Depot | $60 | $90,96212 claims |
| AstraZenecaFarxiga | $148 | $84,70680 claims |
| AmgenProlia | $287 | $43,64326 claims |
| Alvogen IncTeriparatide | $77 | $39,96320 claims |
| MerckJanuvia | $200 | $30,80529 claims |
| AbbVieSynthroid | $119 | $4,94566 claims |
| Sanofi-aventis U.S. LLCLantus | $572 | $4,80423 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 952 endocrinology, diabetes & metabolism providers in California.
Other endocrinology, diabetes & metabolism in Upland
- Juan FriasSan Diego$1.4M
- Joselito CabaccanSan Jose$1.4M
- Daniel NadeauNewport Beach$1.2M
- Yehuda HandelsmanTarzana$1M
- Helen BaronRancho Mirage$958K
- Ken FujiokaSan Diego$747K
- Minou TranPico Rivera$663K
- James ChuMonterey$639K
- Anthony HeaneyLos Angeles$588K
- Daniel Einhornla Jolla$578K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.